Sigrid raises SEK 45 million to scale up its groundbreaking technology for metabolic health

Stockholm, January 7, 2026 – Sigrid, a Swedish innovation company in consumer health, today announces that the company has raised SEK 45 million in new capital. This brings the total capital invested in the company to approximately SEK 250 million. The investment comes from both existing and new international investors and reflects strong confidence in Sigrid’s technology and rapid commercial growth in the US.

Metabolic health has emerged as a global concern, and more and more consumers, patients and healthcare providers are demanding solutions that actually make a difference to blood sugar and weight – and that are based on science. Sigrid’s dietary supplement Glucose Stabiliser has quickly gained widespread use, both through direct sales to consumers and through a growing network of physicians in the US. Over the past twelve months, sales of Glucose Stabiliser have more than tripled, demonstrating strong demand and repeat use in a rapidly growing market.

“We are seeing a clear shift in how people relate to metabolic health,” says Sana Alajmovic, co-founder and CEO of Sigrid. Blood sugar control and sustainable weight have become important issues for many, and the demand for solutions with clear clinical evidence is increasing. With our non-systemic SiPore® technology, we have a unique opportunity to meet this need. The capital injection enables us to continue growing in the US while developing new applications based on our SiPore® platform.

Focus on regulatory progress and new applications

Having recently submitted its technical dossier for CE marking in the EU, Sigrid is now taking the next step towards regulatory approval for a brand new over-the-counter medical device. The product is intended to support weight loss and metabolic health in adults with overweight and elevated blood sugar, as part of a structured lifestyle program.

At the same time, Sigrid is broadening the use of the SiPore® platform beyond metabolic health. New opportunities are being developed in areas such as oral health, veterinary medicine and food technology. The company is currently in dialogue with several leading players in consumer health, nutrition and pharmaceuticals regarding licensing and distribution.